Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

IsoPlexis receives $4 million grant re IsoLIght

IsoPlexis has received $4 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center as a part of the commercialization...

| By Bill Kelly

Tangen Biosciences closes $9 million Series A

Tangen Biosciences has closed a $9 million Series A equity round led by Connecticut Innovations (CI), with participation of current and new stockholders, including VC23, Axiom,...

| By Bill Kelly

FDA clears Arvinas breast cancer treatment

Arvinas reports that the FDA has cleared the company’s Investigational New Drug application for ARV-471, an oral estrogen receptor PROTAC® protein degrader, designed for treatment of...

| By Bill Kelly

UConn taps into cell communication

A new technology discovered by a team including UConn School of Dental Medicine researchers records cellular communication in real time – providing a closer look...

| By Bill Kelly

Intensity Therapeutics to collaborate with Merck

Intensity Therapeutics reports it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the...

| By Bill Kelly

UConn alcohol research center continues run

Despite increasing competition for federal research dollars, the Alcohol Research Center at UConn Health endures well into its fifth decade with an unprecedented continuation of...

| By Bill Kelly

CT creates new workforce training entity

Connecticut lawmakers have seeded a newly created workforce fund with $1 million, and created a new board within the state’s Department of Labor to make grants...

| By Bill Kelly

UConn ranked top 10 for biological data research

According to CSRankings, an organization which compiles a metrics-based rankings of the top computer science programs in the world, the University of Connecticut ranks among...

| By Bill Kelly

Cybrexa closes $13.4m B1 funding round

Cybrexa Therapeutics has completed a $13.4 million Series B1 financing. “This level of financial support from our investors demonstrates the continued enthusiasm and validation for...

| By Bill Kelly

Shoreline Biome to Launch Product Suite

Shoreline Biome plans to unveil the market’s first end-to-end sample prep kit at the upcoming ASM Microbe 2019. The kit, Shoreline Complete, is an end-to-end...